MEDICAL ANALYSIS Good morning everyone. The OrtoBiologica was the last season as an emerging alternative to the option to address the EOA and it is possible to exercise in replication assistant replication and have given promising results and there are modifying effects of potential disease. There are several types of mesenchyme cells but the most used and preferred are now the micro-fragmented ones because they have minimal adipose morbidity they have cells of higher and more dangerous mesenchyme and have a great deal of this tissue available. Adipose tissue is a simple technique, saving time. Mechanical manipulation preserves structural prototypes without the use of enzymatic or other types of mechanical treatment and there is a closed system to avoid contamination of this tissue. There is a step by step procedure. After the lawyer we have a mechanical processing which is very gentle and allows to separate the adipose tissue from the blood cells and maintains the cluster of adipose tissue. And then we have a normal injection. The point of this study was a single randomized control treatment with a microfragmented fat tissue with a single injection versus a plasma plasma with a single injection and to evaluate the clinical army and disease progression in neo-aid patients with a clinical assessor and a radiological assessor who were worn. We evaluated 180 patients 18 symptomatic patients with unilateral neo-aid badly or females between the ages of 18 and 75 with a calculus disease and a conservative treatment flaw and we evaluated through two years follow-up with clinical Army and also X-ray and MRI imaging evaluation. Of these 118 patients 10 patients lost follow-up so we evaluated 53 patients with fragmented fat cells and a PRP group of 55 and both groups were similar for age, BMI, and Calgary Lawrence doctorate. The adverse events we found 10 sick adverse events in the fat group and 6 sick adverse events in the plasma group there is no significant difference between the two groups. In adverse events we have 8 adverse events in the adipose group and this means that they received a different injection and perhaps a surgical treatment. We have 8 adverse events for fragmented fat cell while 14 in plasma rich plasma group but this is still not a significant difference. And in each group through the two year process we maintained the results and there is no statistical difference between the two groups and the MRI examination and evaluation found no significant improvement or deterioration in OAS severity. But if we look at the patient with Calgary Lawrence 3 and 4 we found that adipose group has better results in 6 months than plasma rich plasma group with a better last objective 15 than 8% and better results in MCID result 75 than 35 but this means that the severity OR influenced the clinical outcomes. So, in conclusion the adipose group and the rich plasma group provided clinical improvements up to 24 months we have a comparable number of errors and adverse events and there is no difference anywhere between clinical findings and tests. The adipose group provided better clinical results in 6 months in moderate O severity and the adipose group can be used every 12 months for maintenance of benefits and among some limitations of this study this is the largest randomized control cohort on this tissue type but surely we need of other high-level evidence to maintain the use of this device. A thousand thanks.

micro-fragmented fat tissue

treatment option

clinical improvement

disease progression

maintenance of benefits